You are here: Industry Insights > Takeda

News List

Takeda partners up to develop "next generation" CAR T solid tumour therapy pharmafile
September 05, 2017
Takeda is set to partner with Noile-Immune Biotech in the development of a “next generation” chimeric antigen receptor T-cell (CAR T) therapy for effectively treating solid tumours, it has emerged.
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's worldpharmanews
August 30, 2017
AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341
Astrazeneca, Takeda Establish Collaboration to Develop, Commercialize MEDI1341 americanpharmaceuticalreview
August 30, 2017
AstraZeneca and Takeda have entered an agreement to jointly develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
Samsung-Takeda R&D pact, GSK-Alibaba vaccine union, Gland’s renewed M&A deal fiercepharma
August 28, 2017
With a newly formed drug co-development deal, Samsung Bioepis is finally moving into novel drug R&D.
NICE flip-flops on Takeda's Adcetris—with restrictions fiercepharma
August 28, 2017
NICE issued negative draft guidance on Takeda's Adcetris last August.
Takeda submits NDA for Vedolizumab to treat moderate-to-severe UC in Japan pharmaceutical-technology
August 23, 2017
Takeda Pharmaceutical has filed a new drug application (NDA) for vedolizumab with Japan’s Ministry of Health, Labour and Welfare to treat adult patients with moderately to severely active ulcerative colitis (UC).
Samsung jumps into novel drug R&D through Takeda deal fiercebiotech
August 22, 2017
Samsung Bioepis has begun its long-anticipated move into novel drug R&D. The offshoot of South Korean conglomerate Samsung is taking its first steps beyond the lower risk, lower reward world of biosimilars by teaming up with Takeda to co-develop drugs aga
Samsung Bioepis joins hands with Takeda for biotech drugs biospectrumasia
August 22, 2017
The partnership will develop novel biologic drugs in "unmet disease areas".
Samsung Bioepis, Takeda Sign Agreement to Co-Develop Multiple Novel Biologic Therapies americanpharmaceuticalreview
August 22, 2017
Samsung Bioepis has entered into a strategic collaboration agreement with Takeda to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas.
Zai Lab’s $115M IPO, Takeda-Stanford R&D deal, Chinese firms’ bids for Arbor fiercepharma
August 21, 2017
Pfizer alum Samantha Du's cancer biotech Zai Lab has filed for a $115 million U.S. IPO.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page